INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Ultragenyx Pharmaceutical Inc. and its officers or directors, following disappointing Phase 3 study results for setrusumab, which led to a significant drop in the company's stock price [1][3][4]. Group 1: Company Performance - Ultragenyx announced results from two Phase 3 studies for setrusumab, a treatment for bone metabolism conditions, on December 29, 2025 [3]. - Neither study achieved statistical significance for the primary endpoints related to the reduction in annualized clinical fracture rate compared to placebo or bisphosphonates [3]. - Both studies met their secondary endpoints, showing significant improvements in bone mineral density against comparators [3]. Group 2: Stock Market Reaction - Following the announcement of the study results, Ultragenyx's stock price fell by $2.02 per share, representing a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud by Ultragenyx and its management [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].